NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for ...

BOUCHERVILLE, QC, Aug. 26, 2025 /CNW/ - Delpharm is proud to announce a major milestone in the modernization of its Boucherville facility, made possible by a $60 million government contribution ...

French CDMO Delpharm, which already has a dozen sites across Europe, is planning a big expansion with a deal to pick up five more, including one in North America, along with 1,300 employees in a deal ...

BOUCHERVILLE, QC, March 17, 2025 /CNW/ - The Government of Canada and Delpharm, a worldwide leader in contract manufacturing and development of medicines, cordially invite media representatives to a ...

Japanese drugmaker Astellas Pharma sold off its Netherlands manufacturing facility to French CDMO Delpharm Industries for an undisclosed price. The 46,337-square-meter facility is in Meppel, ...

Viewed through a human resources lens, French pharmaceutical company Delpharm’s first foray into the North American market represents a unique challenge of global expansion and regional adaptation.

This agreement is intended to be executed and see the impact of any financial transfers by the fiscal year ending March 31, 2024. Astellas Pharma announced on May 25, 2023 that Astellas B.V., Astellas ...

PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs ...

The pharmaceutical services firms Famar and Delpharm confirm that they are in talks about the sale of five Famar finished-drug manufacturing plants to Delpharm. The sites—three in France, one in the ...

Delpharm Group selected for large-scale production of firibastat tablets to support clinical phase and future commercial needs Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a ...